Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, tolerability, and pharmacokinetics of three dose regimens of AZD1446 as add-on to donepezil in mild to moderate Alzheimer's disease
2009-015525-37Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of azd1446 in Alzheimer's disease (AD) (4 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of AZD1446 add-on to donepezil over 4 weeks and Effect of AZD1446 on pharmacokinetics of donepezil. Started Oct 2009; status: completed.
02
Drugs
azd1446
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2009-015525-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015525-37.